Health Business Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health Business Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Affymetrix Inc.
Wellcome Trust Sanger Institute Uses Affymetrix Technology to Reveal Changes in 800 Cancer Cell Lines
October 10th, 2008
Affymetrix Inc. (Nasdaq:AFFX) announced that the Wellcome Trust Sanger Institute has developed a catalog of structural genomic changes in almost 800 cancer cell lines using the company's Genome-Wide Human SNP Array 6.0. Cancer cell lines are invaluable reagents in analyzing the molecular biology of the disease as well as important tools in developing new healing methods. The core set of cancer cell lines developed by the Cancer Genome Project includes samples from most types of human cancer. Combined with more than 400 normal control samples, nearly 1,250 were analyzed using Affymetrix technology. The SNP Array 6.0 features more than 1.8 million markers for genetic...
Source: Health Business Week (2008-10-10)
|
